AR014270A1 - Sustancia inhibidora de metaloproteasas de matriz, composicion farmaceutica, uso en la fabricacion de medicamentos, procedimiento parafabricarla y compuestos intermediarios - Google Patents

Sustancia inhibidora de metaloproteasas de matriz, composicion farmaceutica, uso en la fabricacion de medicamentos, procedimiento parafabricarla y compuestos intermediarios

Info

Publication number
AR014270A1
AR014270A1 ARP990100048A ARP990100048A AR014270A1 AR 014270 A1 AR014270 A1 AR 014270A1 AR P990100048 A ARP990100048 A AR P990100048A AR P990100048 A ARP990100048 A AR P990100048A AR 014270 A1 AR014270 A1 AR 014270A1
Authority
AR
Argentina
Prior art keywords
alkyl
alkoxy
formula
optionally substituted
conh2
Prior art date
Application number
ARP990100048A
Other languages
English (en)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9800510.1A external-priority patent/GB9800510D0/en
Priority claimed from GBGB9811843.3A external-priority patent/GB9811843D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of AR014270A1 publication Critical patent/AR014270A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/12—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. N-hydroxyamidines
    • C07C259/18—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. N-hydroxyamidines having carbon atoms of hydroxamidine groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/32—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D317/34—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Una sustancia que es un compuesto de formula (I), y sales farmacéuticamente aceptables del mismo, o un solvato de cualquier entidad, en la que R1 es H,OH, alquilo C1-4, alcoxi C1-4 o alquenilo C2-4; R2 es alquilo C1-6 opcionalmentesusti tuido con fluor, indolilo, imidazolilo, SO2 (alquilo C1-4),cicloalquilo C5-7, o por un grupo OH, SH, CONH2, CO2H, NH2 o NHC (=NH)NH2 opcionalmente protegido, cicloalquilo C5-7 opcionalmente sustituido conalquilo C1-6, o es benciloopcionalmente sustituido con OH opcionalmente protegido, alcoxi C1-6, benciloxi o benciltio, donde los grupos protectoresopcionales para dichos grupos OH, SH, CONH2, NH2 y NHC(=NH) se seleccionan entre alquilo C1-6, bencilo o alcanoiloC1-6, y donde l os grupos protectoresopcionales para dicho CO2H se seleccionan entre alquilo C1-6 o bencilo; cada uno de R3, R5 y R6 se selecciona independientemente entre H y F;R4 es CH3, Cl oF; X es HO o HONH; Y es un enlace directo u O, Z esun grupo de formul a (a), en la que R10 es alquilo C1-4, alcoximetilo C1-4, hidroxi(alquilo C2-4),carboxi(alquilo C1-4) o (amino o dimetilamino)alquilo C2-4; y R11 es fenilo, naftilo o piridilo opcionalmente sustituidos por hasta tressustituyentesseleccionados inde pendientemente entre halo y metilo; o formula (b); R14 es H, OH, CH3 o halo; Ar es un grupo de formula (c), (d) o (e), en la que A es N oCR12; B es N o CR13, con la condicion de que A y B no sean N a la vez, cadauno de R7 y R9 es, independiente mente, H o F, cada uno de R8, R12 y R13 es,independientemente, H, CN, alquilo C1-6, hidroxi(alquilo C1-6), hidroxi (alcoxi C1-6), alcoxi C1-6(alcoxi C1-6), (amino o dimetilamino)alquilo C1-6,CONH2, OH, halo,alcoxi C1-6, (alcoxi C1-6)metilo, piperazinilcarbonio, piperdinilo, C(NH2)=NOH o C(=NH)NHOH, con la condicion de que al menos dos
ARP990100048A 1998-01-09 1999-01-07 Sustancia inhibidora de metaloproteasas de matriz, composicion farmaceutica, uso en la fabricacion de medicamentos, procedimiento parafabricarla y compuestos intermediarios AR014270A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9800510.1A GB9800510D0 (en) 1998-01-09 1998-01-09 Therapeutic agents
GBGB9811843.3A GB9811843D0 (en) 1998-06-02 1998-06-02 Therapeutic agents

Publications (1)

Publication Number Publication Date
AR014270A1 true AR014270A1 (es) 2001-02-07

Family

ID=26312925

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990100048A AR014270A1 (es) 1998-01-09 1999-01-07 Sustancia inhibidora de metaloproteasas de matriz, composicion farmaceutica, uso en la fabricacion de medicamentos, procedimiento parafabricarla y compuestos intermediarios

Country Status (37)

Country Link
US (1) US6350907B1 (es)
EP (1) EP1047665B1 (es)
JP (1) JP3621884B2 (es)
KR (1) KR100385662B1 (es)
CN (1) CN1284942A (es)
AP (1) AP1059A (es)
AR (1) AR014270A1 (es)
AT (1) ATE252547T1 (es)
AU (1) AU736511B2 (es)
BG (1) BG104575A (es)
BR (1) BR9813719A (es)
CA (1) CA2317604C (es)
CO (1) CO4990971A1 (es)
CZ (1) CZ20002459A3 (es)
DE (1) DE69819206T2 (es)
DK (1) DK1047665T3 (es)
DZ (1) DZ2701A1 (es)
EA (1) EA002971B1 (es)
ES (1) ES2209244T3 (es)
HN (1) HN1998000199A (es)
HR (1) HRP20000460A2 (es)
HU (1) HUP0101300A3 (es)
IL (1) IL136889A0 (es)
IS (1) IS5531A (es)
MA (1) MA26594A1 (es)
NO (1) NO20003506L (es)
NZ (1) NZ504683A (es)
OA (1) OA11435A (es)
PA (1) PA8466101A1 (es)
PE (1) PE20000176A1 (es)
PL (1) PL342763A1 (es)
PT (1) PT1047665E (es)
SI (1) SI1047665T1 (es)
SK (1) SK10112000A3 (es)
TN (1) TNSN99002A1 (es)
TR (1) TR200001909T2 (es)
WO (1) WO1999035124A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6352976B1 (en) 1998-12-31 2002-03-05 Aventis Pharmaceuticals Inc. Selective inhibitors of MMP-12
JP2002534435A (ja) * 1998-12-31 2002-10-15 アベンティス・ファーマスーティカルズ・インコーポレイテツド Ｍｍｐ−１２の選択的阻害剤
JP2001055327A (ja) * 1999-06-11 2001-02-27 Fuji Chemical Industries Ltd 新規なヒドロキサム酸誘導体を含む医薬
GB0025310D0 (en) * 2000-10-16 2000-11-29 Pfizer Ltd Process
US6452041B1 (en) 2000-10-16 2002-09-17 Pfizer Inc. Olefination process to itaconate and succinate derivatives
DK1368336T3 (da) * 2001-02-16 2006-10-02 Allelix Neuroscience Inc Thiophensubstituerede aminderivater som GlyT-1-inhibitorer
GB0126389D0 (en) * 2001-11-02 2002-01-02 Pfizer Ltd Wafer
PA8578101A1 (es) * 2002-08-13 2004-05-07 Warner Lambert Co Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz
US20040138103A1 (en) * 2002-11-07 2004-07-15 Procyte Corporation Compositions containing peptide copper complexes and metalloproteinase inhibitors and methods related thereto
ATE457716T1 (de) 2002-12-30 2010-03-15 Angiotech Int Ag Wirkstofffreisetzung von schnell gelierender polymerzusammensetzung
PL379863A1 (pl) * 2003-08-23 2006-11-27 Vernalis (R & D) Limited Pochodne kwasu hydroksamowego jako inhibitory metaloproteinazy
ES2545688T3 (es) * 2006-09-29 2015-09-15 F. Hoffmann-La Roche Ag Método de evaluación del riesgo de progresión de enfermedad de pacientes con artritis reumatoide
CN104788333B (zh) * 2015-03-19 2017-03-22 中国医科大学 2‑取代‑9,10‑蒽醌类化合物、制备方法及其用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5892112A (en) 1990-11-21 1999-04-06 Glycomed Incorporated Process for preparing synthetic matrix metalloprotease inhibitors
GB9215665D0 (en) 1992-07-23 1992-09-09 British Bio Technology Compounds
WO1994012169A1 (en) 1992-11-25 1994-06-09 Merck & Co., Inc. Carboxy-peptidyl derivatives as antidegenerative active agents
GB9308695D0 (en) 1993-04-27 1993-06-09 Celltech Ltd Peptidyl derivatives
DE69419473T2 (de) 1993-04-27 2000-03-16 Celltech Therapeutics Ltd. Peptidylderivate als inhibitoren von metalloproteinase
GB9320660D0 (en) 1993-10-07 1993-11-24 British Bio Technology Inhibition of cytokine production
US6037472A (en) * 1993-11-04 2000-03-14 Syntex (U.S.A.) Inc. Matrix metalloprotease inhibitors
UA48121C2 (uk) 1993-11-04 2002-08-15 Сінтекс (С.Ш.А.) Інк. Інгібітори матричних металопротеаз і фармацетична композиція на їх основі
EP0822186B1 (en) 1994-01-20 2000-03-15 British Biotech Pharmaceuticals Limited L-tert-leucine-2-pyridylamide
KR970700652A (ko) 1994-01-22 1997-02-12 포올 리틀우드 금속단백질 분해효소 억제제
ATE181055T1 (de) 1994-05-28 1999-06-15 British Biotech Pharm Succinyl hydroxamsäure-, n-formyl-n-hydroxy- aminocarbonsäure- und succinsäureamid-derivate und ihre verwendung als metalloprotease- inhibitoren
US5461746A (en) * 1995-01-17 1995-10-31 Tdw Delaware, Inc. Magnetic cleaning pig
US5691381A (en) 1995-04-18 1997-11-25 The Dupont Merck Pharmaceutical Company Hydroxamic and carbocyclic acids as metalloprotease inhibitors
GB9507799D0 (en) * 1995-04-18 1995-05-31 British Biotech Pharm Metalloproteinase inhibitors
WO1996035714A1 (en) 1995-05-10 1996-11-14 Chiroscience Limited Peptide compounds which inhibit metalloproteinase and tnf liberation and their therapeutic uses
EP0824544B1 (en) 1995-05-10 2003-04-16 Darwin Discovery Limited Peptidyl compounds which inhibit metalloproteinase and tnf liberation and their therapeutic use
GB9513331D0 (en) 1995-06-30 1995-09-06 British Biotech Pharm Matrix metalloproteinase inhibitors
US5917090A (en) * 1995-06-30 1999-06-29 British Biotech Pharmaceuticals Ltd. Matrix metalloproteinase inhibitors
US5840974A (en) * 1996-12-04 1998-11-24 Britisch Biotech Pharmaceuticals, Ltd. Metalloproteinase inhibitors

Also Published As

Publication number Publication date
NO20003506D0 (no) 2000-07-07
OA11435A (en) 2004-04-28
DE69819206T2 (de) 2004-04-15
HRP20000460A2 (en) 2001-06-30
KR20010033990A (ko) 2001-04-25
ES2209244T3 (es) 2004-06-16
IL136889A0 (en) 2001-06-14
DK1047665T3 (da) 2004-02-02
SK10112000A3 (sk) 2002-02-05
CZ20002459A3 (cs) 2001-12-12
EP1047665A1 (en) 2000-11-02
DE69819206D1 (de) 2003-11-27
AU736511B2 (en) 2001-07-26
NZ504683A (en) 2002-06-28
CN1284942A (zh) 2001-02-21
NO20003506L (no) 2000-07-07
AP1059A (en) 2002-04-22
ATE252547T1 (de) 2003-11-15
DZ2701A1 (fr) 2003-09-01
IS5531A (is) 2000-06-13
BR9813719A (pt) 2000-10-17
HUP0101300A2 (hu) 2001-08-28
HN1998000199A (es) 2000-11-03
CA2317604C (en) 2004-12-21
PE20000176A1 (es) 2000-03-10
US6350907B1 (en) 2002-02-26
AU2277699A (en) 1999-07-26
BG104575A (en) 2001-02-28
PT1047665E (pt) 2004-01-30
EA002971B1 (ru) 2002-12-26
TNSN99002A1 (fr) 2005-11-10
EP1047665B1 (en) 2003-10-22
CO4990971A1 (es) 2000-12-26
JP2002500215A (ja) 2002-01-08
PA8466101A1 (es) 2000-05-24
TR200001909T2 (tr) 2000-12-21
KR100385662B1 (ko) 2003-05-28
JP3621884B2 (ja) 2005-02-16
EA200000628A1 (ru) 2001-02-26
WO1999035124A1 (en) 1999-07-15
PL342763A1 (en) 2001-07-02
MA26594A1 (fr) 2004-12-20
CA2317604A1 (en) 1999-07-15
AP9901436A0 (en) 1999-03-31
SI1047665T1 (en) 2004-02-29
HUP0101300A3 (en) 2002-11-28

Similar Documents

Publication Publication Date Title
AR014270A1 (es) Sustancia inhibidora de metaloproteasas de matriz, composicion farmaceutica, uso en la fabricacion de medicamentos, procedimiento parafabricarla y compuestos intermediarios
AR030959A1 (es) Derivados de aminoalcoholes, procedimiento para prepararlos, el uso de los mismos para preparar medicamentos y las composiciones farmaceuticas que las contienen
TR199800990T2 (xx) Metaloproteinaz inhibit�rleri, bunlar� i�eren farmas�tik bile�imler, bunlar�n farmas�tik kullan�mlar� ve bunlar�n �retiminde kullan�labilecek y�ntemler ve ara �r�nler.
HRP20050191B1 (hr) Novi derivati benzoimidazola korisni kao antiproliferativna sredstva
ECSP034744A (es) Antagonistas de nmda/nr2b no arilo-heterociclico n-sustituidos
GEP20053600B (en) 3-(4-Amidopyrrol-2-Ylmethlidene)-2- Indolinone Derivatives as Protein Kinase Inhibitors
AR057753A2 (es) Derivados de quinazolina, proceso para su preparacion y composiciones farmaceuticas que los contienen
ES2191356T3 (es) Compuestos heterociclicos para la inhibicion de la secrecion de acidos gastricos, procedimientos para su preparacion y composiciones farmaceuticas de ellos.
DK0495776T3 (da) Stabiliserende nitrogenoxid/primær amin-komplekser, der er anvendelige som cardiovaskulære midler
AR009783A1 (es) Compuesto, composiciones farmaceuticas y metodos para efectuar una actividad neuronal en un animal
AR041566A1 (es) Derivados de indol utiles para el tratamiento de enfermedades
DK1427708T3 (da) Amino-phthalazinon-derivater som kinase-inhibitorer, fremgangsmåde til deres fremstilling og farmaceutiske sammensætninger der indeholder det samme
AR039124A1 (es) Derivados de adamantano, procedimiento de preparacion y composiciones farmaceuticas que los contienen
GEP20063890B (en) Hiv protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis
PL315636A1 (en) Cosmetic or pharmaceutic compositions containing magnipherine or its derivatives
SE9203825L (sv) Dubbelt verkande inhibitorer foer no-syntas och cyklooxygenas, foerfarande foer framstaellning daerav och terapeutiska kompositioner innehaallande desamma
IL166784A0 (en) New purine derivatives
AR054445A1 (es) Formulaciones de un inhibidor de src/abl
NO308248B1 (no) Forbindelser som er anvendbare som antiproliferative midler og GARFT-inhibitorer, samt farmasøytisk preparat
AR012489A1 (es) Tiofenopiridinas antagonistas del factor de liberacion de corticotropina. procedimiento para su preparacion, el uso de las mismas en la preparacionde un medicamento, composicion farmaceutica que las comprende, procedimiento para la preparacion de dicha composicion, un compuesto intermediario y
IL166783A0 (en) New purine derivatives
AR012681A1 (es) Inhibidores de proteasas, composicion farmaceutica que los comprende, su uso para la fabricacion de un medicamento y compuesto intermediario
MEP22508A (en) Novel 1,2,3-substituted indolizine derivatives, inhibitors of fgfs, method for making same and pharmaceutical compositions containing same
DK78995A (da) Anvendelse af visse substituerede arylalkylaminer til fremstilling af et lægemiddel med neurobeskyttende virkning
DK0902684T3 (da) Hexahydro-pyrido (4,3-B) indolderivater som antipsykotiske lægemidler

Legal Events

Date Code Title Description
FA Abandonment or withdrawal